期刊
VACCINES
卷 8, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/vaccines8030492
关键词
flavivirus; mosquito-borne diseases; subunit vaccines
资金
- Fundacao Butantan
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [16/20045-7, 18/24683-3, 19/18205-4, 15/02352-7, 16/23560-0]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [16/23560-0, 19/18205-4, 16/20045-7] Funding Source: FAPESP
This article aims to review the present status of anti-flavivirus subunit vaccines, both those at the experimental stage and those already available for clinical use. Aspects regarding development of vaccines to Yellow Fever virus, (YFV), Dengue virus (DENV), West Nile virus (WNV), Zika virus (ZIKV), and Japanese encephalitis virus (JEV) are highlighted, with particular emphasis on purified recombinant proteins generated in bacterial cells. Currently licensed anti-flavivirus vaccines are based on inactivated, attenuated, or virus-vector vaccines. However, technological advances in the generation of recombinant antigens with preserved structural and immunological determinants reveal new possibilities for the development of recombinant protein-based vaccine formulations for clinical testing. Furthermore, novel proposals for multi-epitope vaccines and the discovery of new adjuvants and delivery systems that enhance and/or modulate immune responses can pave the way for the development of successful subunit vaccines. Nonetheless, advances in this field require high investments that will probably not raise interest from private pharmaceutical companies and, therefore, will require support by international philanthropic organizations and governments of the countries more severely stricken by these viruses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据